|
Biotech Showcase
|
2
|
Zenith Epigenetics
|
Dec 17, 2018 12:24PM
|
|
Re: Bioasis To Present at Investor & Industry Conferences in January 2019
|
2
|
BIOASIS TECHNOLOGIES INC
|
Dec 17, 2018 12:31PM
|
|
Re: 2019 Potential Events
|
2
|
Resverlogix Corp.
|
Dec 17, 2018 12:32PM
|
|
Re: Biotech Showcase
|
3
|
Zenith Epigenetics
|
Dec 17, 2018 12:32PM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
4
|
Resverlogix Corp.
|
Dec 17, 2018 03:11PM
|
|
Re: Lowest volume in a long time?
|
2
|
Resverlogix Corp.
|
Dec 18, 2018 10:16AM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
4
|
Resverlogix Corp.
|
Dec 18, 2018 02:26PM
|
|
The importance of sub-group analyses
|
6
|
Resverlogix Corp.
|
Dec 18, 2018 05:18PM
|
|
Re: "top line data on or before January 31, 2019" A Covenant of the loan
|
3
|
Resverlogix Corp.
|
Dec 18, 2018 05:27PM
|
|
The HDL hypothesis lives on
|
3
|
Resverlogix Corp.
|
Dec 18, 2018 07:50PM
|
|
Re: The importance of sub-group analyses
|
3
|
Resverlogix Corp.
|
Dec 18, 2018 08:42PM
|
|
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
|
2
|
Resverlogix Corp.
|
Dec 19, 2018 08:53AM
|
|
Re: Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
|
1
|
Resverlogix Corp.
|
Dec 19, 2018 09:02AM
|
|
Re: IR reply...
|
3
|
Resverlogix Corp.
|
Dec 19, 2018 07:42PM
|
|
Re: Third Eye and Topline
|
3
|
Resverlogix Corp.
|
Dec 20, 2018 11:57AM
|
|
Re: Third Eye and Topline
|
2
|
Resverlogix Corp.
|
Dec 20, 2018 02:30PM
|
|
Coronary Artery Calcium Score
|
6
|
Resverlogix Corp.
|
Dec 21, 2018 10:34AM
|
|
Holding steady
|
4
|
Resverlogix Corp.
|
Dec 21, 2018 04:36PM
|
|
Re: Holding steady
|
3
|
Resverlogix Corp.
|
Dec 21, 2018 08:35PM
|
|
Re: Holding steady
|
4
|
Resverlogix Corp.
|
Dec 22, 2018 08:28AM
|
